Tao R, Hjorth S
Department of Pharmacology, University of Göteborg, Sweden.
Naunyn Schmiedebergs Arch Pharmacol. 1992 Feb;345(2):137-43. doi: 10.1007/BF00165728.
The putative existence of a functional alpha 2-adrenoceptor-mediated modulation of 5-HT release in vivo from serotonergic neuronal terminals in the ventral hippocampus was investigated using intracerebral microdialysis in chloral hydrate-anaesthetised rats. The alpha 2-adrenoceptor agonist clonidine (0.01-0.3 mg/kg, SC) dose-dependently decreased the 5-HT output. The response to clonidine was antagonized by systemic or local administration of the alpha 2-adrenoceptor antagonist idazoxan (0.1 mg/kg, SC, or 10 mumol/l, via the dialysis perfusion medium). Similarly, the 5-HT release-suppressing response to the thiazole alpha 2-adrenoceptor agonist jingsongling (0.1 mg/kg, SC) was blocked by idazoxan (0.1 mg/kg, SC). The mixed beta-adrenoceptor/5-HT1 receptor antagonist pindolol (8.0 mg/kg, SC) did not affect the clonidine-induced reduction of 5-HT release. Tyrosine hydroxylase inhibition by means of alpha-methyl-para-tyrosine (alpha-MT; 250 mg/kg, IP) caused a drastic reduction (greater than 80%) in dialysate 3,4-dihydroxyphenyl acetic acid (DOPAC) output but did not affect the 5-HT output per se over 3 h post-injection. Nor did the alpha-MT pretreatment prevent, but instead significantly enhanced, the 5-HT release-suppressing effect of clonidine. The results demonstrate that the release of 5-HT from serotonergic nerve terminals in rat ventral hippocampus in vivo is modulated by alpha 2-adrenoceptors, probably both by heteroreceptors on the axon terminals of the serotonergic neurones and by other alpha 2-adrenoceptor sites situated pre- and/or postsynaptic to the noradrenergic terminals. Our results also suggest that while functionally operative, these sites may receive little physiological tone, at least in chloral hydrate-anaesthetised rats.
在水合氯醛麻醉的大鼠中,运用脑内微透析技术,研究了腹侧海马中5-羟色胺能神经元终末是否存在功能性α2-肾上腺素能受体介导的体内5-羟色胺释放调节作用。α2-肾上腺素能受体激动剂可乐定(0.01 - 0.3mg/kg,皮下注射)呈剂量依赖性地降低5-羟色胺输出量。全身性或局部给予α2-肾上腺素能受体拮抗剂咪唑克生(0.1mg/kg,皮下注射,或10μmol/L,通过透析灌注液)可拮抗对可乐定的反应。同样,噻唑类α2-肾上腺素能受体激动剂京苏灵(0.1mg/kg,皮下注射)引起的5-羟色胺释放抑制反应也被咪唑克生(0.1mg/kg,皮下注射)阻断。β-肾上腺素能受体/5-羟色胺1受体混合拮抗剂吲哚洛尔(8.0mg/kg,皮下注射)不影响可乐定诱导的5-羟色胺释放减少。通过α-甲基-对酪氨酸(α-MT;250mg/kg,腹腔注射)抑制酪氨酸羟化酶,导致透析液中3,4-二羟基苯乙酸(DOPAC)输出量急剧减少(大于80%),但在注射后3小时内对5-羟色胺输出量本身无影响。α-MT预处理也未阻止可乐定的5-羟色胺释放抑制作用,反而显著增强了该作用。结果表明,大鼠腹侧海马中5-羟色胺能神经终末释放5-羟色胺在体内受α2-肾上腺素能受体调节,可能通过5-羟色胺能神经元轴突终末上的异源性受体以及去甲肾上腺素能终末突触前和/或突触后的其他α2-肾上腺素能受体位点。我们的结果还表明,虽然这些位点在功能上起作用,但至少在水合氯醛麻醉的大鼠中,它们可能很少受到生理调节。